- Home
- SNTI vs GOEV Comparison
SNTI vs GOEV Comparison
Compare SNTI & GOEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- GOEV
- Stock Information
- Founded
- SNTI 2016
- GOEV 2017
- Country
- SNTI United States
- GOEV United States
- Employees
- SNTI N/A
- GOEV N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- GOEV
- Sector
- SNTI Health Care
- GOEV
- Exchange
- SNTI Nasdaq
- GOEV Nasdaq
- Market Cap
- SNTI 19.1M
- GOEV 19.6M
- IPO Year
- SNTI N/A
- GOEV N/A
- Fundamental
- Price
- SNTI $4.67
- GOEV $1.35
- Analyst Decision
- SNTI Strong Buy
- GOEV Buy
- Analyst Count
- SNTI 1
- GOEV 6
- Target Price
- SNTI $12.00
- GOEV $103.10
- AVG Volume (30 Days)
- SNTI 115.8K
- GOEV 3.4M
- Earning Date
- SNTI 11-14-2024
- GOEV 11-13-2024
- Dividend Yield
- SNTI N/A
- GOEV N/A
- EPS Growth
- SNTI N/A
- GOEV N/A
- EPS
- SNTI N/A
- GOEV N/A
- Revenue
- SNTI N/A
- GOEV $1,864,000.00
- Revenue This Year
- SNTI $11.52
- GOEV $2,927.65
- Revenue Next Year
- SNTI $78.57
- GOEV $922.67
- P/E Ratio
- SNTI N/A
- GOEV N/A
- Revenue Growth
- SNTI N/A
- GOEV 259.15
- 52 Week Low
- SNTI $1.52
- GOEV $1.04
- 52 Week High
- SNTI $16.94
- GOEV $102.12
- Technical
- Relative Strength Index (RSI)
- SNTI 56.65
- GOEV 29.03
- Support Level
- SNTI $3.72
- GOEV $1.04
- Resistance Level
- SNTI $4.93
- GOEV $1.79
- Average True Range (ATR)
- SNTI 0.46
- GOEV 0.21
- MACD
- SNTI 0.01
- GOEV 0.35
- Stochastic Oscillator
- SNTI 81.82
- GOEV 41.33
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About GOEV Canoo Inc.
Canoo Inc is a mobility technology company providing with a proprietary modular electric vehicle platform and connected services initially focused on commercial fleet, government and military customers. The Company has developed a breakthrough EV platform that it believes will enable it to rapidly iterate and bring new products, addressing multiple use cases, to market faster than competition and at lower cost.